This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Clinical Studies

Sigmond H. Nadler, MD; George E. Moore, MD, PhD

AMA Arch Surg. 1970;100(3):244-248.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Numerous modalities have been used in the treatment of cancer and for some time now host factors, including immunity in a classical sense, have been thought to be of importance.

"Host factors" may be involved in the malignant process but the evidence accumulated so far is indirect and the mechanisms poorly understood. The existence of resistance factors has been suggested because (1) occasional spontaneous regression of established tumor does occur, (2) widespread metastases may appear many years after the apparent successful treatment of a primary lesion, (3) some patients may survive for long periods of time even after incomplete removal of their cancer, (4) occasional regression of metastatic disease may occur after the primary tumor has been treated, and (5) evidence exists that large numbers of tumor cells may be extruded into the lymphatic and vascular systems without the development of metastases.¹²

Most of the initial animal experiments performed . . . [Full Text PDF of this Article]

Author Affiliations
Philadelphia

From the Department of Surgery, Roswell Park Memorial Institute, New York State Department of Health, Buffalo, NY. Dr. Nadler is now at Jefferson Medical College, Philadelphia.

Footnotes
Accepted for publication Dec 15, 1969.

Reprint requests to Jefferson Medical College, 1025 Walnut St, Philadelphia 19107 (Dr. Nadler).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?